Table 1 Clinical trials of CAR-T cell therapy in solid tumors (ClinicalTrials.gov)
CAR-T product | Clinical trial identifier | Targeted antigen | Disease | Cell source | Clinical trial phase | Status | Estimated enrollment (EE)/ Actual enrollment (AE)/ Treated patients (TP) | Study objectives |
|---|---|---|---|---|---|---|---|---|
MSLN-CAR-T cells | NCT05531708 | MSLN | Mesothelin-positive advanced refractory solid tumors | Autologous T cells | Phase 1 | Recruiting | 20 (EE) | Evaluation of the safety and efficacy of novel mesothelin CAR-T in patients with mesothelin-positive advanced refractory solid tumors. |
MSLN-CAR-T cells | NCT05373147 | MSLN | Mesothelin-positive solid tumors | Autologous T cells | Early Phase 1 | Recruiting | 21 (EE) | Evaluation of the safety and tolerability of autologous MSLN-CAR-T cells secreting PD-1 nanobodies (αPD1-MSLN-CAR T cells) in patients with solid tumors. |
MSLN CAR-T cells | NCT04489862 | MSLN | Non-small cell lung cancer Mesothelioma | Autologous T cells | Early Phase 1 | Recruiting | 10 (EE) | Evaluation of the safety and tolerability of autologous MSLN-CAR-T cells secreting PD-1 nanobodies (αPD1-MSLN-CAR T cells) in patients with solid tumors. |
MSLN CAR-T cells | NCT05141253 | MSLN | MSLN-positive solid tumors | RD133 autologous T cells | Early Phase 1 | Recruiting | 24 (EE) | Evaluation of the safety and efficacy of RD133 MSLN CAR-T cells in subjects with relapsed or refractory MSLN-positive solid tumors. |
MSLN CAR-T cells | NCT05166070 | MSLN | Solid tumors | RD133 autologous T cells | Early Phase 1 | Recruiting | 24 (EE) | Evaluation of the Safety and efficacy of RD133 in subjects with relapsed or refractory MSLN-Positive solid tumors. |
MSLN CAR T cells secreting PD-1 nanobodies | NCT04489862 | MSLN | Non-small-cell lung cancer Mesothelioma | Autologous T cells | Early Phase 1 | Recruiting | 10 (EE) | Exploratory study of MSLN-CAR-T Cells secreting PD-1 nanobodies for the treatment of MSLN-positive advanced solid tumors. |
PD-1 antibody expressing MSLN CAR-T cells | NCT03615313 | MSLN | MSLN-positive advanced recurrent or refractory malignant solid tumors | Autologous T cells | Phase 1 Phase 2 | Unknown | 50 (EE) 1 (TP) | Evaluation of the safety and efficacy of infusion of autologous T cells engineered to target mesothelin and express PD-1 antibodies in adult patients with advanced recurrent or refractory malignant solid tumors, which were positive expression of mesothelin. |
MSLN CAR-T cells | NCT02159716 | MSLN | Metastatic Pancreatic (Ductal) Adenocarcinoma Epithelial ovarian cancer Malignant epithelial pleural mesothelioma | Autologous T cells | Phase 1 | Completed | 19 (AE) 15 (TP) | Evaluation of the safety and feasibility of intravenously administered lentiviral transduced CART-meso cells administered with and without cyclophosphamide in a 3 + 3 dose escalation design in patients with metastatic pancreatic cancer, serous epithelial ovarian cancer, or pleural mesothelioma. |
αPD1-MSLN-CAR T Cells | NCT04503980 | MSLN | Colorectal cancer Ovarian cancer | Autologous T cells | Early Phase 1 | Unknown | 10 (EE) | Evaluation of the safety and tolerability of autologous mesothelin (MSLN)-targeted chimeric antigen receptor (MSLN-CAR) T cells secreting PD-1 nanobodies (αPD-1-MSLN-CAR T cells) in patients with solid tumors. |
CTLA-4/PD-1 antibodies expressing MSLN CAR-T cells | NCT03182803 | MSLN | Advanced solid tumors | Autologous T cells | Phase 1 Phase 2 | Unknown | 40 (EE) | Assessment of the efficacy and safety of the CTLA-4 and PD-1 antibodies expressing mesothelin-CAR-T (mesoCAR-T) for patients with mesothelin positive, advanced recurrent or refractory malignant solid tumors |
PD-1 antibody expressing MSLN CAR-T cells | NCT03030001 | MSLN | Solid tumors Adult advanced cancer | Autologous T cells | Phase 1 Phase 2 | Unknown | 40 (EE) | Determination of the safety and efficacy of infusion of autologous T cells engineered to express immune checkpoint antibody and chimeric antigen receptor targeting mesothelin in adult patients with mesothelin positive, recurrent, or refractory malignant tumors. |
MSLN CAR-T cells | NCT03545815 | MSLN | MSLN-positive multiple solid tumors | Autologous T cells | Phase 1 | Unknown | 10 (EE) | Evaluation of the feasibility and safety of CRISPR-Cas9 mediated PD-1 and TCR gene-knocked out CAR-T cells in patients with mesothelin positive multiple solid tumors. |
GD2/PSMA bi-specific CAR-T cell | NCT05437315 | GD2/PSMA | GD2 and PPSMA-positive tumors | Autologous T cells | Phase 1 Phase 2 | Recruiting | 60 (EE) | Assessment of the feasibility, safety, and efficacy of anti-GD2/PSMA bi-specific CAR-T cell therapy in patients with GD2 and PSMA-positive tumors. Evaluation of the function of the anti-GD2/PSMA bi-specific CAR-T cells and their persistency in patients. |
GD2 CAR-T cells | NCT02107963 | GD2 | Sarcoma Osteosarcoma Neuroblastoma Melanoma | Autologous T cells | Phase 1 | Completed | 15 (AE) | Evaluation of the antitumor effects, persistence, and safety of GD2 CAR-T cells in children and young adults with GD2-positive solid tumors. |
GD2 CAR-T01 cells | NCT03373097 | GD2 | Neuroblastoma recurrent GD2-positive solid tumors Osteosarcoma Ewing sarcoma | Autologous T cells | Phase 1 Phase 2 | Recruiting | 42 (EE) | Evaluation of the safety and efficacy of GD2-CART01, a CAR-T cell treatment targeting GD2 in pediatric or young adult patients with high-risk and/or relapsed/refractory neuroblastoma. |
GD2 CAR T cells | NCT04196413 | GD2 | Glioma of spinal cord Glioma of Brainstem | Autologous T cells | Phase 1 | Recruiting | 45 (EE) 4 (TP) | Evaluating whether GD2-CAR T cells can be successfully made from immune cells collected from children and young adults with H3K27M-mutant diffuse intrinsic pontine glioma (DIPG) or spinal H3K27M-mutant diffuse midline glioma (DMG). H3K27Mmutant testing will occur as part of standard of care prior to enrollment. |
GD2 CAR T cells | NCT00085930 | GD2 | Neuroblastoma | Autologous T cells | Phase 1 | Active, not recruiting | 19 (TP) | Study of blood T-cells and EBV specific CTLs Expressing GD-2 Specific Chimeric T cell receptors in patients with neuroblastoma |
CLDN18.2 CAR-T cells | NCT04467853 | CLDN18.2 | Claudin18.2-positive advanced solid tumors | LCAR-C18S cells | Phase 1 | Recruiting | 34 (EE) | Evaluation of the safety, tolerability, pharmacokinetics, and anti-tumor efficacy profiles of the cell-based LCAR-C18S (hereinafter “LCAR-C18S”) in subjects with claudin18.2-positive advanced solid tumors. |
CLDN18.2 CAR-T cells | NCT05472857 | CLDN18.2 | Gastric cancer Pancreatic cancer Advanced ovarian carcinoma Gastroesophageal junction adenocarcinoma | Autologous T cells | Phase 1 | Recruiting | 30 (EE) | Evaluation of the safety and efficacy of autologous claudin18.2 CAR-T cell therapy in advanced solid tumors with positive CLDN18.2 expression. |
CLDN18.2 CAR-T cells | NCT03874897 | CLDN18.2 | Advanced solid Tumor | Autologous T cells | Phase 1 | Recruiting | 123 (EE) 37 (TP) | Evaluation of the safety, efficacy, and pharmacokinetics of autologous humanized anti-claudin18.2 CAR-T cells in advanced solid tumor. |
CLDN18.2 CAR-T cells | NCT04581473 | CLDN18.2 | Gastric adenocarcinoma Pancreatic cancer Gastroesophageal junction adenocarcinoma | CT041 autologous T cells | Phase 1b Phase 2 | Recruiting | 192 (EE) | Evaluation of the efficacy, safety, and pharmacokinetics of CT041 autologous CAR-T cells. Injection in patients with CLDN18.2-positive advanced gastric/ gastroesophageal junction adenocarcinoma and pancreatic cancer. |
CLDN18.2 CAR-T cells | NCT05199519 | CLDN18.2 | Solid tumors | Autologous T cells | Phase 1 | Recruiting | 30 (EE) | Evaluate the safety, tolerance, pharmacokinetics, and preliminary efficacy of IBI345 in patients with CLDN18.2-positive solid tumors. |
CLDN18.2 CAR-T cells | NCT05620732 | CLDN18.2 | Advanced pancreatic carcinoma Advanced gastric carcinoma | Autologous T cells | N/A | Recruiting | 20 (EE) | Evaluation of the efficacy and safety of claudin18.2 CAR-T in advanced pancreatic cancer and gastric carcinoma. |
CLDN18.2 CAR-T cells | NCT05472857 | CLDN18.2 | Gastric cancer Pancreatic cancer Advanced ovarian carcinoma Gastroesophageal junction adenocarcinoma | Autologous T cells | Phase 1 | Recruiting | 30 (EE) | Evaluation of the safety and efficacy of autologous claudin18.2 CAR-T cell therapy in advanced solid tumors with positive CLDN18.2 expression. |
CLDN6 CAR-T cells | NCT04503278 | CLDN6 | Solid Tumor | Autologous T cells | Phase 1 Phase 2 | Recruiting | 96 (EE) | Evaluation of safety and preliminary efficacy of CLDN6 CAR-T With or Without CLDN6 RNA-LPX in patients with CLDN6-positive relapsed or refractory advanced solid tumors. |
CEA CAR-T cells | NCT05415475 | CEA | Colorectal cancer Esophageal cancer Stomach cancer Pancreatic cancer Metastatic tumor Recurrent cancer | Autologous T cells | Phase 1 | Recruiting | 36 (EE) | Verification of the safety and efficacy of CAR-T cells in the treatment of CEA-positive advanced malignant tumors, and to obtain the recommended dose and infusion scheme of CAR-T cells for the treatment of patients with CEA-positive advanced malignant tumors. Administration method: intravenous infusion or intraperitoneal injection. |
CEA CAR-T cells | NCT04348643 | CEA | Solid tumor Lung cancer Colorectal cancer Liver cancer Pancreatic cancer Gastric cancer Breast cancer | Autologous T cells | Phase 1 Phase 2 | Recruiting | 40 (EE) | Evaluation of the efficacy and safety of CEA-targeted CAR-T cells for patients with relapsed/refractory CEA-positive cancer and to obtain the recommended dose and infusion plan. |
CEA CAR-T cells | NCT05538195 | CEA | Gastric cancer Colon cancer Rectal cancer Esophageal cancer Pancreatic cancer | Autologous T cells | Phase 1 Phase 2 | Recruiting | 60 (EE) | Evaluation of the safety and efficacy of CEA-targeted CAR-T cell in CEA-positive advanced malignant tumors. |
CEA CAR-T cells | NCT05396300 | CEA | Colorectal cancer Esophageal cancer Stomach cancer Pancreatic cancer Metastatic tumors Recurrent cancer | Autologous T cells | Phase 1 | Completed | 60 (EE) | Evaluation of the safety and tolerability of CAR-T in patients with CEA-positive advanced malignant solid tumors, and to obtain the maximum tolerated dose of CAR-T and phase II recommended dose. |
CEA CAR-T cells | NCT02349724 | CEA | Lung cancer Colorectal cancer Gastric Cancer Breast Cancer Pancreatic Cancer | Autologous T cells | Phase 1 | Unknown | 75 (EE) 10 (TP) | Verification of the safety of CEA targeted chimeric antigen receptor T cells and to determine the proper dosage of CAR T cells infused |
CEA CAR-T cells | NCT02416466 | CEA | Liver metastases | Autologous T cells | Phase 1 | Completed | 8 (AE) 6 (TP) | Study of anti-CEA CAR-T cells hepatic artery infusions and yttrium-90 SIR-Spheres in patients with CEA-expressing liver metastases |
CEA CAR-T cells | NCT02850536 | CEA | Liver metastases | Autologous T cells | Phase 1b | Completed | 5 (AE) 1 (TP) | Study of anti-CEA CAR-T cell infusions delivered via the hepatic artery or splenic vein using the Sure-fire Infusion System (SIS) for patients with CEA-expressing liver metastases or pancreas cancer. |
ROR1 CAR-T cells | NCT05274451 | ROR1 | Triple-negative breast cancer Non-small cell lung cancer Metastatic non-small cell carcinoma of the lung Breast cancer Advanced lung carcinoma Recurrent NSCLC Relapse/recurrence breast cancer | LYL797 autologous T cells | Phase 1 | Recruiting | 54 (EE) | Assessment of the safety and efficacy of LYL797, ROR1-targeting CAR-T cells, in adults with relapsed and/or refractory solid-tumor malignancies. |
ROR1 CAR-T cells | NCT02706392 | ROR1 | Advanced ROR1-positive TNBC and NSCLC | Autologous T cells | Phase 1 | Terminated | 21 (AE) 5 (TP) | Evaluation of the safety and anti-tumor activity of adoptively transferred autologous ROR1 CAR-T cells in pts. with advanced ROR1+ TNBC and NSCLC. |
ROR2 CAR-T cells | NCT03960060 | ROR2 | Recurrent or refractory solid tumors | CCT301–59 autologous T cells | Active, not recruiting | 18 (EE) | Evaluation of the safety and preliminary therapeutic efficacy of CCT301–59 T cells in adult subjects with relapsed and refractory stage IV metastatic solid tumors (soft tissue sarcoma, gastric cancer, pancreatic cancer, bladder cancer). | |
NKG2DL CAR-T cells | NCT05382377 | NKG2DL | CRC, advanced NKG2DL-positive solid tumors | KD-025 autologous cell | Phase 1 | Recruiting | 18 (EE) | Evaluation of the safety and effectiveness of NKG2D-based CAR-T cell infusion in the treatment of advanced NKG2DL-positive solid tumors. |
NKG2DL+/CLDN18.2+ CAR-T cells | NCT05583201 | NKG2D/CLDN18.2 | NKG2D/CLDN18.2-positive solid tumor | KD-496 autologous cells | Phase 1 | Recruiting | 18 (EE) | Evaluation of the safety and effectiveness of NKG2D/CLDN18.2-based CAR-T cell infusion in the treatment of advanced NKG2DL+/CLDN18.2+ solid tumors. |
NKG2DL CAR-T cells | NCT04107142 | NKG2DL | Colorectal Cancer Triple negative breast cancer Sarcoma Nasopharyngeal carcinoma Prostate cancer Gastric cancer | Haploidentical / Allogeneic T cells | Phase 1 | Unknown | 10 (EE) | Evaluation of the haploidentical / allogeneic Natural Killer Group 2D Ligand (NKG2DL)-targeting chimeric antigen receptor-grafted Gamma Delta (γδ) T Cells (CTM-N2D) in subjects with relapsed or refractory solid tumour |
CD70 CAR-T cells | NCT05420545 | CD70 | Metastatic tumor Advanced solid tumor Renal cell carcinoma Ovarian cancer Cervix cancer | Autologous T cells | Phase 1 | Recruiting | 36 (EE) | Evaluation of the safety and tolerability of CAR-T in patients with CD70-positive advanced/metastatic solid tumors, and to obtain the maximum tolerated dose of CAR-T and phase II recommended dose. |
CD276 CAR-T cells | NCT04691713 | CD276 | CD276-positive advanced solid tumors | Autologous T cells | N/A | Unknown | 5 (EE) | Evaluation of the safety and effectiveness of targeting CD276 auto-chimeric antigen receptor T cells in the treatment of CD276-positive advanced solid tumors. |
HER2 CAR-T cells | NCT04650451 | HER2 | HER2-positive gastric cancer HER2-positive breast cancer HER-2 protein overexpression solid tumor | BPX-603 autologous T cells | Phase 1 Phase 2 | Recruiting | 220 (EE) | Investigation of the safety, tolerability, and clinical activity of HER2-specific dual-switch CAR-T cells, BPX-603, administered with rimiducid to subjects with previously treated, locally advanced or metastatic solid tumors which are HER2 amplified/overexpressed. |
HER2 CAR-T cells | NCT04511871 | HER2 | Solid tumor Gastric cancer Breast cancer Ovarian cancer Sarcoma | Autologous T cells | Phase 1 | Recruiting | 15 (EE) | Assessment of the safety, tolerability, and anti-tumor activity of autologous CAR-T cells (CCT303–406) in patients with relapsed or refractory HER2 Positive solid tumors. |
HER2 CAR-T cells | NCT03740256 | HER2 | Solid tumors | Autologous T cells | Phase 1 | Recruiting | 45 (EE) | Study of the effect of binary oncolytic adenovirus in combination with HER2-Specific autologous CAR-T Cells in patients with advanced HER2 Positive solid tumors. |
HER2 CAR-T cells | NCT00902044 | HER2 | Advanced sarcoma | Autologous T cells | Phase 1 | Active, not recruiting | 36 (EE) 19 (TP) | Administration of HER2 CAR-T cells for subjects with advanced sarcoma (HEROS) |
HER2 CAR-T cells | NCT01109095 | HER2 | Glioblastoma multiforme | Autologous T cells | Phase 1 | Completed | 16 (AE) 17 (TP) | Evaluation of the safety and antitumor efficacy of autologous HER2-specific chimeric antigen receptor (CAR)–modified virus-specific T cells (VSTs) in patients with progressive glioblastoma |
HER2 CAR-T cells | NCT01935843 | HER2 | Advanced HER-2-positive solid tumors | Autologous T cells | Phase 1 Phase 2 | Unknown | 10 (EE) 11 (TP) | Evaluation of the safety, feasibility, and activity of CAR-T cell immunotherapy targeting human epidermal growth factor receptor 2 (HER2) in patients with advanced biliary tract cancers (BTCs) and pancreatic cancers (PCs) |
HER2 CAR-T cells | NCT03500991 | HER2 | HER2-positive recurrent/refractory pediatric CNS tumors | Autologous T cells | Phase 1 | Recruiting | 48 (EE) 3 (TP) | Assessing the feasibility, safety, and tolerability; secondary objectives include assessing CAR-T cell distribution and disease response |
EGFR-TGFβR-KO CAR-T cells | NCT04976218 | EGFR | EGFR-positive solid tumors | Autologous T cells | Phase 1 | Recruiting | 30 (EE) | Evaluation of the anti-tumor activities and safety profiles of CAR-EGFR-TGFβR-KO T cell in previously treated advanced EGFR positive solid tumors. CAR-EGFR-TGFβR-KO T cell engineered by knocking out TGF-β receptor II through CRISPR/Cas9. |
Anti-CTLA-4/PD-1 expressing EGFR-CAR-T | NCT03182816 | EGFR | EGFR-positive advanced solid tumors | Autologous T cells | Phase 1 Phase 2 | Unknown | 40 (EE) 9 (TP) | Assessment of the efficacy and safety of the CTLA-4 and PD-1 antibodies expressing EGFR-CAR-T for patients with EGFR positive advanced recurrent or refractory malignant solid tumors |
EGFR CAR-T cells | NCT01869166 | EGFR | EGFR-positive advanced solid tumors | Autologous T cells | Phase 1 Phase 2 | Unknown | 60 (EE) 14 (TP) | Evaluation of the safety, feasibility of the chimeric antigen receptor T cells transduced with the anti-EGFR and their in vivo survival duration. |
EGFRvIII CAR-T cells | NCT02209376 | EGFRvIII | Residual or reccurent EGFRvIII- positive Glioma | Autologous T cells | Phase 1 | Terminated | 11 (EE) 10 (TP) | Evaluation of the safety and feasibility of CART-EGFRvIII (autologous T cells transduced with a lentiviral vector to express a chimeric antigen receptor specific for EGFRvIII) in the treatment of patients with EGFRvIII+ glioblastoma who have had their first recurrence as determined by standard imaging or have residual disease after initial resection. |
PD-1 antibody expressing EGFR CAR-T Cells | NCT02873390 | EGFR | EGFR-positive advanced solid tumors | Autologous T cells | Phase 1 Phase 2 | Unknown | 20 (EE) | Evaluation of the safety and effectiveness of cell therapy using herinCAR-PD1 cells to treat advanced cancer. |
PD-1 antibodies expressing EGFR CAR-T Cells | NCT02862028 | EGFR | EGFR-positive advanced solid tumors (Lung, Liver and Stomach) | Phase 1 Phase 2 | Unknown | 20 (EE) | Evaluation of the safety and effectiveness of cell therapy using herinCAR-PD1 cells to treat relapsed or refractory cancer | |
VEGFR1/PD-L1 CAR-T cells | NCT05477927 | VEGFR1 and PD-L1 | Malignant peritoneal effusion Malignant ascites Serous cavity metastatises | Autologous T cells | Phase 1 | Recruiting | 58 (EE) | Dose-escalation and expansion study of specific dual-targeting VEGFR1 and PD-L1 CAR-T in cancer patients with pleural or peritoneal metastases. |
EGFR/B7-H3 CAR-T cells | NCT05341492 | EGFR and B7-H3 | Advanced lung cancer Advanced triple-negative breast cancer | Autologous T cells | Early Phase 1 | Recruiting | 30 (EE) | Evaluation of the safety and efficacy of EGFR/B7H3 CAR-T in patients with EGFR/ B7-H3-positive advanced solid tumors (Lung and Triple-negative Breast Cancer). |
B7-H3 CAR-T cells | NCT04897321 | B7-H3 | Pediatric solid tumor Sarcoma | Autologous T cells | Phase 1 | Recruiting | 32 (EE) | Evaluation of the use of autologous T cells genetically engineered to express B7-H3-CARs for patients ≤21 years old, with relapsed/refractory B7-H3-positive solid tumors. Evaluation of the safety and maximum tolerated dose of B7-H3-CAR-T cells. Finding the highest dose of B7-H3-CAR T cells that are safe to give to patients with B7-H3-positive solid tumors. |
B7-H3 CAR-T cells | NCT04483778 | B7-H3 | Recurrent/Refractory solid tumors in children and young adults | Allogeneic T cells | Phase 1 | Recruiting | 68 (EE) | Evaluation of the safety, feasibility, and efficacy of administering T cell products derived from the research participant’s blood that have been genetically modified to express a B7-H3-specific receptor CAR that will target and kill solid tumors that express B7-H3. |
B7-H3 CAR-T cells | NCT05190185 | B7-H3 | Malignant melanoma lung cancer, or colorectal cancer | TAA06 autologous T cells | Phase 1 | Recruiting | 18 (EE) | Evaluation of the safety and tolerability of TAA06 CAR-T cells targeting B7-H3 in patients with advanced solid tumors. Evaluation of the distribution, proliferation, and persistence of B7-H3-targeted CAR T cells and their efficacy. |
CD276 CAR-T | NCT04691713 | CD276 | Solid tumors | Autologous T cells | N/A | Recruiting | 5 (EE) | Evaluation of the safety and effectiveness of targeting CD276 auto-CAR-T cells in the treatment of CD276-positive advanced solid tumors. |
CTLA-4 and PD-1 antibodies expressing MUC1-CAR-T Cells | NCT03179007 | MUC1 | MUC1-positive advanced recurrent or refractory malignant solid tumors. | Autologous T cells | Phase 1 Phase 2 | Unknown | 40 (EE) | Evaluation of the safety and efficacy of infusion of autologous T cells engineered to express immune checkpoint antibodies (CTLA-4 and PD-1) and chimeric antigen receptor targeting MUC1 in adult patients with MUC1 positive, advanced recurrent or refractory malignant solid tumors. |
PD-1 -Knockout MUC1 CAR-T cells | NCT03706326 | MUC1 | Advanced esophageal cancer | Autologous T cells | Phase 1 Phase 2 | Unknown | 20 (EE) | Assessment of the safety and efficacy of the immunotherapies using anti-MUC1 CAR T cells and /or PD-1 knockout engineered T cells in the treatment of patients with advanced esophageal cancer. |
MUC1 CAR T Cells | NCT02587689 | MUC1 | Hepatocellular carcinoma Non-small Cell Lung Cancer Pancreatic Carcinoma Triple-negative invasive breast carcinoma | Autologous T cells | Phase 1 Phase 2 | Unknown | 20 (EE) | Determination of whether autologous T cells bearing chimeric antigen receptor that can specifically recognize (Mucin 1) MUC1 is safe and effective for patients with relapsed or refractory solid tumor. |
MUC1 CAR T Cells | NCT02617134 | MUC1 | Malignant glioma of brain Colorectal carcinoma Gastric Carcinoma | Autologous T cells | Phase 1 Phase 2 | Unknown | 20 (EE) | Evaluation of the safety and effectiveness of CAR-T cell immunotherapy in patients with MUC1 positive relapsed or refractory solid tumors. |
P-MUC1C-ALLO1 CAR-T cells | NCT05239143 | MUC1C | Breast cancer Ovarian cancer Non-small cell lung cancer Colorectal cancer Pancreatic cancer Renal cell carcinoma Nasopharyngeal cancer Head and neck squamous cell carcinoma Gastric cancer | Allogeneic T cells | Phase 1 | Recruiting | 100 (EE) 3 (TP) | Determination of the recommended phase 2 dose of P-MUC1C-ALLO1 an allogeneic CAR-T cell therapy designed to target cancer cells expressing Mucin1 cell surface-associated C-Terminal (MUC1-C) antigen. |
TnMUC1 CAR-T cells | NCT04025216 | TnMUC1 | Advanced TnMUC1-positive solid tumors | Autologous T cells | Phase 1 | Active, not recruiting | 112 (EE) | Identification of the dose and regimen of CART-TnMUC1 cells that can be safely administered intravenously following the lymphodepletion (LD) regimen to patients with (1) advanced TnMUC1+ solid tumors (triple negative breast cancer, epithelial ovarian cancer, pancreatic cancer, and non-small cell lung cancer) and (2) advanced TnMUC1+ multiple myeloma |
Lewis Y CAR-T cells | NCT03851146 | Lewis Y | Advanced cancer | Autologous T cells | Phase 1 | Completed | 20 (EE) | Investigation of the safety, tolerability, and immunological effects of T Lymphocytes transduced with an anti-Lewis Y (LeY) CAR gene (LeY-CAR-T) in patients with LeY antigen expressing advanced solid tumors. |
OX40 CAR-T cells | NCT04952272 | OX40 | Lung cancer Hepatocellular carcinoma Solid tumor | Autologous T cells | Phase 1 | Recruiting | 50 (EE) | Evaluation of the safety and clinical effects of intratumor injecting CpG-ODN and in situ release of tumor antigen by interventional ablation or drug-eluting beads to treat advanced solid tumors. With or without infusion of CAR-T cells secreting scFv against OX40. |
EpCAM CAR-T cells | NCT02915445 | EpCAM | Malignant neoplasm of nasopharynx TNM staging distant metastasis Breast cancer Recurrent gastric cancer with metastasis | Autologous T cells | Phase 1 | Recruiting | 30 (EE) | Determination of the safety of CAR-T cells recognizing EpCAM. |
TM4SF1- and EpCAM- CAR-T cells | NCT04151186 | TM4SF1/ EpCAM | EpCAM-positive Recurrent/Refractory solid tumors | Autologous T cells | N/A | Unknown | 72 (EE) | Evaluation of the Safety and efficacy of CAR-T-cell therapy for the TM4SF1- and EpCAM-positive Recurrent/Refractory solid tumors |
NKG2DL CAR-T cells | NCT05382377 | NKG2DL | Solid tumors | KD-025 autologous T cells | Early Phase 1 | Recruiting | 30 (EE) | Evaluation of the safety and efficacy of KD-025 CAR-T Therapy in advanced NKG2DL-positive solid tumors. |
PSCA CAR-T cells | NCT02744287 | PSCA | Metastatic Castration-resistant Prostate cancer Metastatic prostate cancer | BPX-601 autologous T cells | Phase 1 Phase 2 | Recruiting | 151 (EE) | Evaluation of the feasibility, safety, and activity of PSCA-Specific CAR Engineered T Cells (BPX-601) in subjects with previously treated advanced solid tumors. |
GUCY2C CAR-T cells | NCT05287165 | GUCY2C | Advanced solid tumors Digestive system neoplasms Pancreatic cancer Resectable colorectal (colon or rectal) cancer | IM96 autologous T cells | Early Phase 1 | Recruiting | 19 (EE) | Evaluation of the safety and efficacy of IM96 CAR-T Cells therapy in patients with advanced digestive system neoplasms. |
4SCAR-IgT- cells | NCT03356782 | CD133, GD2, MUC1, CD117 | Sarcoma osteoid Sarcoma Ewing Sarcoma | Autologous T cells | Phase1 Phase 2 | Recruiting | 20 (EE) | Evaluation of the safety and efficacy of 4th generation 4SCAR-IgT cells targeting sarcomas. |
IL7, CCL19, IL12-expressing Nectin4 CAR-T cells | NCT03932565 | Nectin4 | Nectin4-positive malignant solid tumors | Autologous T cells | Phase 1 | Unknown | 30 (EE) | Study of the intravenous minimally invasive surgery combined with intratumoral injection of Nectin4/FAP-targeted fourth-generation CAR-T cells (expressing IL7 and CCL19, or IL12) are used to treat Nectin4-positive advanced malignant solid tumors, maximally eliminating residual cancer cells, and preventing recurrence. |
GPC3 CAR-T cells | NCT02932956 | Glypican 3 | Pediatric solid tumors | Autologous T cells | Phase 1 | Active, not recruiting | 10 (EE) | The purpose of this study is to find the biggest dose of GAP T cells that is safe, to see how long they last in the body, to learn what the side effects are and to see if the GAP T cells will help people with GPC3-positive solid tumors. This study enrolls patients who have GPC3-positive solid tumors |
CAR-T cells | NCT03356795 | GD2, PSMA, MUC1, MSLN or other markers | Cervical cancer | Autologous T cells | Phase 1 Phase 2 | Unknown | 20 (EE) | Assessment of the feasibility, safety, and efficacy of CAR T cells immunotherapy in patients who have GD2, PSMA, Muc1, Mesothelin or other markers positive cervical cancer. Another goal of the study is to learn more about the persistence and function of CAR T cells in the body. |
CAR-T cells | NCT04981119 | N/A | Solid tumor Colorectal cancer Non-small cell lung cancer Pancreatic cancer | Autologous T cells | N/A | Recruiting | 200 (EE) | Collect information on how often a solid tumor cancer might lose the Human Leukocyte Antigen (HLA) by next-generation sequencing and perform leukapheresis to collect and store an eligible participant’s own T cells for future use to make CAR-T Cell therapy for their disease treatment. |
N/A | NCT04082910 | N/A | Solid tumor Hematological malignancy | Autologous T cells | Phase 1 Phase 2 | Recruiting | 30 (EE) | Evaluation of the feasibility and efficacy of metoprolol, a beta-1 adrenergic receptor blocker, in the treatment of cytokine release syndrome (CRS) caused by CAR-T cell infusions. Evaluation of the effects of the treatment on the serum levels of Interleukin-6 (IL-6) and other cytokines. |